Fathimanoud, Correspondent, India Pharma Outlook
Selecting a sterile injectable CDMO in India requires a structured evaluation that goes beyond capacity and price. Sterile fill-finish is one of the most technically demanding and regulatory-sensitive steps in pharmaceutical manufacturing.
A single inspection finding, equipment limitation, or quality system gap can delay a program or disrupt patient supply. The decision shapes the product’s path from early clinical batches through global commercial distribution.
The following twelve criteria provide a practical framework for assessing potential partners.
No. | Criterion | What to Evaluate |
1 | Regulatory Approvals & Inspection History | Recent inspections by USFDA, EMA, and other authorities for the specific facility and filling line. Check observation classifications and CAPA. Confirm approvals apply to the exact site and line. |
2 | Sterile Manufacturing Experience | Track record with similar products (small molecules, biologics, potent compounds) at both clinical and commercial scale, across different dosage forms. |
3 | Aseptic Processing Technology | Cleanroom design, personnel and material flows, Contamination Control Strategy. Preference for automated filling that reduces human intervention in Grade A zones. |
4 | Isolator / RABS Capability | Whether the proposed line uses isolators or RABS. Isolators offer higher containment; RABS suit high-speed filling. Request recent media-fill data and equipment qualification status. |
5 | Lyophilization Capacity | Total shelf area, maximum vials per batch, qualification status of lyophilizers, and ability to support cycle development. Capacity should cover clinical to commercial volumes without site changes. |
6 | Vial / Ampoule / PFS / Cartridge Capability | Supported container formats and whether they match product needs (liquid, lyophilized, multi-dose, ready-to-use). Check processing methods and container-closure integrity testing. |
7 | Small- & Large-Volume Injectable Capability | Ability to handle SVP (≤100 ml) and/or LVP (>100 ml). Different equipment and controls are required for each. |
8 | Analytical & Microbiology Infrastructure | On-site or integrated labs for method transfer, release testing, stability work, and environmental monitoring. Capacity for method validation and rapid micro methods. |
9 | Technology-Transfer Capability | Documented process for transferring processes, scale-up, analytical methods, and change control. Clear ownership and success criteria. |
10 | Clinical-to-Commercial Scale-Up | Ability to run both small clinical batches and large commercial lots on compatible equipment and quality systems without later site changes. |
11 | Global Market Experience | Successful supply to target regulated markets (US, EU, Japan, etc.) and corresponding facility/line approvals. Familiarity with different pharmacopoeial standards. |
12 | Capacity Availability & Business Continuity | Current available capacity, lead times, slot reservation policies and contingency plans if demand exceeds forecast. Network redundancy or alternative lines add security. |
Also Read: Why Global Pharma is Moving to India: The 2026 India CDMO Boom and Market Outlook
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")